Clinical Trials Logo

Filter by:
NCT ID: NCT00171405 Completed - Hypertension Clinical Trials

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

Start date: June 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.

NCT ID: NCT00171327 Completed - Hypertension Clinical Trials

Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

Start date: July 2004
Phase: Phase 4
Study type: Interventional

Patients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or fluvastatin for 8 weeks. At week 8 all patients were administered a combination treatment with valsartan 160 mg and fluvastatin 80 mg.

NCT ID: NCT00169494 Completed - Clinical trials for Infections, Papillomavirus

Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18

Start date: September 2004
Phase: Phase 3
Study type: Interventional

Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the consistency of consecutive vaccine lots and the non-inferiority of modified manufacturing processes of GSK Biologicals HPV-16/18 vaccine and the vaccine safety, over 12 months, in young adolescents and women of 10-25 years of age at study start. Approximately 750 study subjects will receive different lots of the HPV vaccine administered intramuscularly according to a 0-1-6 month schedule.

NCT ID: NCT00168844 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Tiotropium / Respimat One-Year Study

Start date: January 2003
Phase: Phase 3
Study type: Interventional

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

NCT ID: NCT00168831 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Tiotropium / Respimat One-Year Study

Start date: February 2003
Phase: Phase 3
Study type: Interventional

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

NCT ID: NCT00168701 Completed - Multiple Sclerosis Clinical Trials

Efficacy and Safety of BG00012 in MS

Start date: October 1, 2004
Phase: Phase 2
Study type: Interventional

Determine the efficacy, safety, and tolerability of BG00012 in MS patients.

NCT ID: NCT00168103 Completed - Clinical trials for Hereditary Angioedema

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Start date: June 2005
Phase: Phase 2/Phase 3
Study type: Interventional

HAE is a rare disorder characterized by functional C1 esterase inhibitor deficiency. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of swelling of the larynx. This clinical Phase 2/Phase 3 study was designed to provide clinically relevant data on dosing, efficacy and safety in subjects with HAE.

NCT ID: NCT00168038 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP). The main efficacy parameter is the proportion of patients responding to treatment by an increase of platelet count to ≥ 50 x 10^9/L.

NCT ID: NCT00163527 Completed - Asthma Clinical Trials

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

Start date: April 2003
Phase: Phase 3
Study type: Interventional

Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma. The aim of the study is to investigate the effect of roflumilast taken orally together with low dose inhaled corticosteroids on lung function. Roflumilast will be administered at one dose level once daily together with inhaled corticosteroids at one dose level twice daily. The study duration consists of a baseline period (2 to 6 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.

NCT ID: NCT00163202 Completed - Clinical trials for Hypercholesterolemia

Comparative Atorvastatin Pleiotropic Effects

CAP
Start date: June 2002
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented coronary artery disease.